115 related articles for article (PubMed ID: 36582284)
1. Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention.
Dawei W; Shuangman M; Huiyao H; Dandan C; Yu T; Ning L
Front Med (Lausanne); 2022; 9():1082445. PubMed ID: 36582284
[TBL] [Abstract][Full Text] [Related]
2. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.
Partridge AH; Sepucha K; O'Neill A; Miller KD; Motley C; Swaby RF; Schneider BP; Dang CT; Northfelt DW; Sledge GW
JAMA Oncol; 2015 Jun; 1(3):369-74. PubMed ID: 26114161
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Unblinding in Randomized Controlled Trials: A Research Ethics Case.
Bhatia A; Appelbaum PS; Wisner KL
Ethics Hum Res; 2021 Mar; 43(2):28-34. PubMed ID: 33683016
[TBL] [Abstract][Full Text] [Related]
5. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
7. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
Feys F; Bekkering GE; Singh K; Devroey D
Syst Rev; 2014 Feb; 3():14. PubMed ID: 24555576
[TBL] [Abstract][Full Text] [Related]
8. Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials.
Bello S; Moustgaard H; Hróbjartsson A
J Clin Epidemiol; 2017 Jan; 81():42-50. PubMed ID: 27555081
[TBL] [Abstract][Full Text] [Related]
9. Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Dinnett EM; Mungall MM; Kent JA; Ronald ES; McIntyre KE; Anderson E; Gaw A;
Clin Trials; 2005; 2(3):254-9. PubMed ID: 16279148
[TBL] [Abstract][Full Text] [Related]
10. Changes in beliefs identify unblinding in randomized controlled trials: a method to meet CONSORT guidelines.
Rees JR; Wade TJ; Levy DA; Colford JM; Hilton JF
Contemp Clin Trials; 2005 Feb; 26(1):25-37. PubMed ID: 15837450
[TBL] [Abstract][Full Text] [Related]
11. Implications for blinding in clinical trials with THC-containing cannabinoids based on the CANNA-TICS trial.
Müller-Vahl KR; Jakubovski E; Fremer C; Lenz-Ziegenbein M; Großhennig A; Klages C; Koch A; Haas M; Pisarenko A
Front Neurosci; 2022; 16():793703. PubMed ID: 36213751
[TBL] [Abstract][Full Text] [Related]
12. Blind outcome assessment: the development and use of procedures to maintain and describe blinding in a pragmatic physiotherapy rehabilitation trial.
Minns Lowe CJ; Wilson MS; Sackley CM; Barker KL
Clin Rehabil; 2011 Mar; 25(3):264-74. PubMed ID: 20971749
[TBL] [Abstract][Full Text] [Related]
13. The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications.
Bello S; Moustgaard H; Hróbjartsson A
J Clin Epidemiol; 2014 Oct; 67(10):1059-69. PubMed ID: 24973822
[TBL] [Abstract][Full Text] [Related]
14. Ethics, consent and blinding: lessons from a placebo/sham controlled CPAP crossover trial.
Djavadkhani Y; Marshall NS; D'Rozario AL; Crawford MR; Yee BJ; Grunstein RR; Phillips CL
Thorax; 2015 Mar; 70(3):265-9. PubMed ID: 25595508
[TBL] [Abstract][Full Text] [Related]
15. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
[TBL] [Abstract][Full Text] [Related]
18. First evidence of Beauvais' hypothesis in a plant model.
Thieves K; Gleiss A; Kratky KW; Frass M
Homeopathy; 2016 Aug; 105(3):270-279. PubMed ID: 27473549
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
